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Bone morphogenetic protein-2 (BMP-2) induces a
switch in differentiation of mesenchymal cells from the
myogenic to the osteogenic lineage. Here we describe
that in C2C12 cells, BMP-2 decreases myogenin expres-
sion induced by des-(1,3)insulin-like growth factor-1
(des-(1,3)IGF-1) or ectopically expressed from a consti-
tutive promoter, even in conditions where myogenin
mRNA levels were unaffected. Addition of BMP-2 de-
creases myogenin protein half-life to 50%, whereas pro-
teasome inhibitors abolish these effects. Forced expres-
sion of Id1, either by transient transfection or under the
control of an inducible system, causes degradation of
myogenin in the absence of BMP-2. In contrast, E47
overexpression blocks the inhibitory effect of BMP-2 on
myogenin levels. Finally, expression of E47 in 293 cells
stabilizes myogenin, an effect that is dependent on the
heterodimerization mediated by their helix-loop-helix.
Our findings indicate that induction of Id1 not only
blocks transcriptional activity but also induces myoge-
nin degradation by blocking formation of myogenin-E47
protein complexes.
Mesenchymal cells differentiate into distinct cell types, such
as adipocytes, osteoblasts, or myoblasts. Differentiation has
two stages; first is the commitment to a particular cell lineage,
and secondly, cells start to express the proteins that character-
ize their final phenotype. Commitment to a specific lineage
depends on mutually exclusive factors. Thus, signals that in-
duce a particular phenotype repress others. For example, sig-
nals that induce the osteoblastic phenotype, such as BMPs
(bone morphogenetic proteins),1 repress myogenic differentia-
tion in vitro (1, 2) and induce bone after implantation in muscle
in vivo (3). The capacity of mesenchymal cells to differentiate
into distinct cell types is a result of the expression and function
of determination genes, which include distinct families of tran-
scription factors known as master genes. Thus, the fate of the
mesenchymal precursors depends on the expression of a
specific combination of master genes: the myogenic basic
helix-loop-helix (bHLH) family for myoblasts, the peroxisome
proliferator-activated receptor- (PPAR-) and CAAAT/
enhancer-binding protein (C/EBP) families for adipocytes, and
core binding factor -1 (Cbfa-1) and Osterix for osteoblasts
(4–6).
The myogenic bHLH family, also known as muscle regula-
tory factors (MRFs), is formed by four members, MyoD, myo-
genin, Myf5, and MRF4 (4, 7). These were identified by their
ability to induce the differentiation of non-muscle cells into a
muscle phenotype (8, 9). Whereas MyoD and Myf5 are involved
in the initial determination state, myogenin and MRF4 partic-
ipate in terminal differentiation (7). The MRFs, which belong
to the superfamily of bHLH transcription factors, contain a
conserved basic DNA-binding domain and a helix-loop-helix
motif, which is essential for dimerization. MRFs heterodimer-
ize with the E family of ubiquitously expressed bHLH factors
(10, 11). Assembly of the heterodimer allows correct juxtaposi-
tion of the two basic regions, which leads to binding and acti-
vation of E-boxes (CANNTG), DNA motifs in the promoters of
skeletal muscle-specific genes (12, 13).
Mesenchymal cells use redundant mechanisms to ensure
that the muscle differentiation program is activated only at the
appropriate moment. These mechanisms probably also control
the timing of other mesenchymal differentiation programs with
the concomitant block of muscle differentiation. The first
checkpoint is the expression of the master genes for the myo-
genic program. Thus, myogenin is absent in proliferating myo-
blasts, and its expression is induced by factors that stimulate
the myogenic program, such as the decrease in growth factors
or presence of IGF-1 (9, 14, 15). Moreover, expression of MyoD
and myogenin mRNA is suppressed by incubation with BMP-2
(16). The second level of control is covalent modification,
mainly phosphorylation of the transcription factors. Thus, myo-
genin is phosphorylated by protein kinase C (17) and calmodulin-
dependent kinase II (CaMKII) (18, 19) in its DNA-binding
domain, thereby inhibiting DNA binding. Similarly, overex-
pression of protein kinase A inhibits the transcriptional activ-
ity of MRF4 (20) and myogenin (21). The third level of control
is through interaction with other proteins that regulate the
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activity of transcription factors. For example, the hypophos-
phorylated form of the retinoblastoma protein (Rb) associates
with MyoD and is required for the efficient transactivation of
E-box-containing muscle-specific promoters (22). Moreover,
several proteins that participate in the control of the cell cycle,
such as Fos, Jun, or the adenoviral protein E1A, directly inter-
act with MRFs and inhibit their transcriptional activity (23–
25). Finally, the helix-loop-helix transcription factors can be
negatively regulated by the Id family of proteins (26–28). Id
members are helix-loop-helix factors that lack the basic region
that allows DNA binding. Thus, Ids heterodimerize with the
E-factors and inhibit their binding to DNA. Ids sequester ubiq-
uitous E-factors (27, 29) and act as dominant negative regula-
tors with respect to the tissue-specific helix-loop-helix proteins
(MyoD, myogenin, etc.).
Here we describe a new posttranscriptional mechanism im-
plicated in the inhibition of the myogenic program by BMP-2,
the abrupt degradation of myogenin by a mechanism that in-
volves the proteasome. This mechanism is dependent on the
induction of Id proteins by BMP-2.
EXPERIMENTAL PROCEDURES
Materials—Human recombinant BMP-2 was obtained from the Ge-
netics Institute, and N-acetyl-Leu-Leu-norleucinal (LLnL) was from
Sigma. Des-(1,3)IGF-1 was from Angelika F. Schutzdeller (Tubingen,
Germany). Cell culture media, fetal bovine serum, glutamine, and an-
tibiotics were obtained from Invitrogen. The other reagents were of
analytical or molecular biology grade and were purchased from Sigma
or Roche Applied Science.
Cell Culture and Transfections—C2C12 mouse cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 20% fetal
bovine serum, 50 units/ml penicillin, and 50 g/ml streptomycin sulfate.
Confluent cells were differentiated in DMEM containing 2% horse
serum in the presence or absence of 2 nM BMP-2 or 2 nM des-(1,3)IGF-1
for the times indicated. For short incubations, C2C12 cells were first
depleted of growth factors for 24 h in DMEM containing 0.1% fetal
bovine serum.
C2C12 cells were transiently transfected after addition of differenti-
ation medium with pIRESbleo-Id1 (the murine Id1 cDNA was obtained
by PCR, sequenced, and subcloned into pIRESbleo from Clontech),
pcDNA3-E47 (a generous gift from Dr. Pura Mun˜oz-Canoves), or
pcDNA3 using polyethylenimine (PEI) (Aldrich) (30). Stable clones of
C2C12 cells were generated by transfecting 10 g of pcDNA3-myogenin
or pcDNA3 and selection using G418 (400 g/ml) for 2–3 weeks. We
used three clones that expressed distinct levels of myogenin (Fig. 2,
Clones 5, 7, and 8) or the C2C12-pcDNA3 control cells.
We generated an inducible clone of Id1 in C2C12 cells (C2C12-
pTISN-Id1) following the Tet-Off protocol described by Chambard and
Pognonec (31). First, we used two distinct vectors that code for tetra-
cycline-regulated transactivator (tTA) and puromycin resistance under
the control of a tTA-responsive promoter (tetO-CMV) to generate C2C12
cells that stably expressed the tTA. After selection of clones resistant to
puromycin, we transfected Id1 cloned in the pTISN vector (which ex-
pressed neomycin resistance), where Id1 was under the control of the
tTA-responsive promoter. After selection, clones expressed Id1 in in-
verse proportion to the tetracycline concentration in the culture me-
dium. The concentration of tetracycline was 100 ng/ml in all experi-
ments. To reverse the effect of tetracycline, cells were incubated for 12 h
in the presence of tetracycline, rinsed five times with phosphate-buff-
ered saline (PBS), and incubated in normal medium in the absence of
tetracycline for the times indicated.
HEK-293 cells were maintained in DMEM supplemented with 10%
fetal bovine serum and antibiotics. Cells were transiently transfected
using polyethylenimine. The expression vectors encoding full-length
E47, E47 lacking the helix-loop-helix (E47HLH, which codes for amino
acids 1–386), or E47 containing the helix-loop-helix (E47HLH, which
codes for amino acids 387–649) were kindly provided by Dr. P. Mun˜oz-
Canoves and tagged with Myc.
Western Blot Analysis—Cells were washed twice in cold PBS and
lysed in Triton X-100 lysis buffer (50 mM Tris-HCl (pH 7.5), 100 mM
NaCl, 50 mM NaF, 5 mM EDTA, 40 mM -glycerophosphate, 200 M
sodium orthovanadate, 100 M phenylmethylsulfonyl fluoride, 1 M
pepstatin A, 1 g/ml leupeptin, 4 g/ml aprotinin, 1% Triton X-100) for
15 min at 4 °C. Western blots were performed as described previously
(2). The blots were incubated with polyclonal Id1 antibody (Santa Cruz
Biotechnology), monoclonal antimyogenin 1F8 antibody (a generous gift
from Dr. Pura Mun˜oz-Canoves, Centre de Regulacio´ Geno`mica, Barce-
lona, Spain), polyclonal E47 antibody (Santa Cruz Biotechnology),
monoclonal anti--actin (Sigma), polyclonal anti-ERK2 (32), or mono-
clonal anti-Myc (Sigma) in blocking solution overnight at 4 °C.
Northern Blot—Total RNA from cells was extracted using the phenol/
chloroform method (33), and Northern blot with 20 g of RNA was
performed as described previously (2). Blots were hybridized to the
mouse myogenin cDNA or rat glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) cDNA labeled with [-32P]dCTP (Amersham Biosciences).
Immunofluorescence Studies—Cells were cultured on glass cover-
slips for 24 h and transfected with the plasmids indicated. 48 h after
transfection, cells were rinsed three times with PBS and fixed in 3%
paraformaldehyde for 20 min. After four washes with PBS, they were
permeabilized with PBS, 0.2% Triton X-100 for 5 min, rinsed four times
with PBS, and blocked for 30 min at room temperature in PBS contain-
ing 2% bovine serum albumin. Coverslips were incubated with mouse
monoclonal 1F8 antimyogenin antibody, rabbit polyclonal anti-Id1 an-
tibody (Santa Cruz Biotechnology), or rabbit polyclonal anti-E47 anti-
body (Santa Cruz Biotechnology) in blocking solution for 1 h at room
temperature, followed by Texas Red- or fluorescein isothiocyanate-con-
jugated anti-mouse or anti-rabbit antibody (Molecular Probes) for 1 h at
room temperature. Finally, cells were incubated with Hoechst 333258
(Sigma) for 5 min at room temperature. Coverslips were mounted using
Mowiol (Calbiochem), and immunofluorescence was visualized with a
Nikon Eclipse E800 microscope.
RESULTS
BMP-2 Induces the Degradation of Myogenin in C2C12
Cells—C2C12 cells incubated for 3 days with a limited supply
of growth factors (2% horse serum) or in the presence of 2 nM
des-(1,3)IGF-1 (a potent myogenic inducer) (15, 34) differenti-
ated to multinucleated myotubes. These myotubes expressed
typical skeletal muscle markers, such as myogenin (Fig. 1A).
Treatment with BMP-2 not only blocked myotube formation (2,
35) and myogenin expression (Fig. 1A) but also stimulated
typical osteoblastic markers, such as osteocalcin or alkaline
phosphatase (2, 36). Simultaneous treatment of cells with both
factors abolished myogenin expression (Fig. 1A), whereas the
osteoblastic markers were maintained (data not shown). Fur-
thermore, the addition of des-(1,3)IGF-1 12 or 24 h after BMP-2
did not reverse its inhibitory effects, and levels of myogenin
remained low. In contrast, addition of BMP-2 12 or 24 h after
IGF-1 caused a progressive decrease in myogenin levels (Fig.
1A). Thus, the effects of BMP-2 on myogenin expression were
dominant over those of des-(1,3)IGF-1.
BMP-2 inhibits transcription of the myogenin gene (16). To
evaluate the time course of the inhibitory effect of BMP-2 on
myogenin expression, we incubated C2C12 cells in the presence
of BMP-2, des-(1,3)IGF-1, or both factors for 4 or 8 h. After a 4-h
incubation, BMP-2 induced Id1, an inhibitor of the family of
helix-loop-helix transcription factors (28, 29, 37), and its ex-
pression was maintained until 8 h (Fig. 1B). Des-(1,3)IGF-1
induced myogenin mRNA and protein at 4 and 8 h (Fig. 1C) but
did not inhibit Id1 induction by BMP-2. Incubation in the
presence of BMP-2 blocked the myogenin protein induction not
only at 8 h but also at 4 h, in conditions where the myogenin
mRNA induction was unaffected (Fig. 1, B and C).
To identify the mechanisms involved in the effect of BMP-2
on myogenin protein levels over short times, we first evaluated
a possible effect of BMP-2 on the IGF-1 signaling pathways.
C2C12 cells were preincubated in the presence of BMP-2 fol-
lowed by the addition of des-(1,3)IGF-1 for 30 min or 1 h. We
did not detect any difference in ERK1/2 or phosphatidylinositol
3-kinase stimulation by des-(1,3)IGF-1 in the presence or ab-
sence of BMP-2 (data not shown). The observation that BMP-2
blocked myogenin protein induction at 4 h, independently of
transcriptional regulation, led us to hypothesize that BMP-2
affects myogenin protein stability. To test this hypothesis, we
generated stable clones of C2C12 that express myogenin under
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the control of an independent promoter (cytomegalovirus pro-
moter of the vector pcDNA3). We generated three independent
clones (Fig. 2A, Clones 5, 7, and 8) with distinct expression
levels of the myogenin mRNA and protein. Myogenin transcrip-
tion from these clones did not respond to BMP-2 (Fig. 2B). In all
the cases BMP-2 caused a time-dependent decrease in the
levels of myogenin protein, which was already observed 4 h
after the addition of BMP-2 (Fig. 2A). The rate of myogenin
decrease depended on the initial levels of myogenin expressed
in each clone. Thus, in those that expressed low levels, the rate
of decrease was faster than in those that expressed high myo-
genin levels (Fig. 2A), indicating the dependence of a limiting
factor that controlled myogenin degradation by BMP-2. To
confirm the data obtained by Western blot experiments, we
performed immunofluorescence studies with antibodies
against myogenin. As described previously (38), myogenin was
immunolocalized in the nucleus of C2C12 cells (Fig. 2C). Incu-
bation for 4 h with BMP-2 caused a significant decrease in the
myogenin signal, without causing a clear effect of protein relo-
calization at the subcellular level.
Myogenin Is Degraded by a Proteasome-dependent Mecha-
nism—To confirm an induction of the degradation of the myo-
genin protein by BMP-2, we incubated cells with BMP-2 for 1 h,
and after this preincubation, we added cycloheximide, a pro-
tein synthesis inhibitor, and then harvested cells after a range
of times. In control conditions myogenin had a short half-life of
about 60 min (Fig. 3A), which is consistent with the findings
of other studies (39). Addition of BMP-2 increased the rate of
myogenin degradation, causing the half-life to fall to 30 min,
confirming that the short term effect of BMP-2 was because of
an increase in myogenin degradation.
The BMP-2-dependent decrease in myogenin protein levels
may be explained by its degradation by a ubiquitin-proteasome
system. Proteasome is one of the systems most often used by
the cellular machinery to control the levels of subtly regulated
proteins (40, 41). To assess this possibility, we preincubated
cells in the presence of LLnL, a potent inhibitor of the 26 S
proteasome (42). Addition of the inhibitor in the absence of
BMP-2 caused a clear increase in the levels of myogenin (Fig.
3B) both in its major 36-kDa form and in a higher Mr form
because of its phosphorylation (data not shown) (39, 43). These
results indicate that myogenin was degraded in basal condi-
tions by a proteasome-dependent mechanism. More impor-
tantly, addition of LLnL before incubation with BMP-2 abol-
ished the effect of the cytokine, and the accumulation of
FIG. 1. BMP-2 blocks myogenin induction by IGF-1. A, C2C12
cells were incubated for 3 days in differentiation medium containing 2%
horse serum in the absence (DM) or presence of 2 nM BMP-2 (BMP) or
2 nM des-(1,3)IGF-1 (IGF). Where indicated, BMP-2 or des-(1,3)IGF-1
was added 12 h (IGF or BMP 60h) or 24 h (IGF or BMP 48h) after
the addition of the differentiation medium containing the other cyto-
kine. Finally, both factors were added simultaneously for 3 days
(BI). After these incubations, cells were lysed, and Western blot was
performed using antimyogenin and anti-ERK2 (as a loading control)
antibodies. B, depleted C2C12 cells were incubated for 4 or 8 h in the
absence (C) or presence of 2 nM BMP-2, 2 nM des-(1,3)IGF-1, or both
(BI). Myogenin, Id1, and ERK2 (as a loading control) were immuno-
detected as described. C, using the same protocol as in B total RNA was
obtained and analyzed by Northern blot. After blotting, myogenin was
detected by hybridization using a specific probe. 18 S ribosomal RNA is
shown as a loading control.
FIG. 2. BMP-2 induces degradation of the myogenin protein. A,
C2C12 clones stably overexpressing myogenin (Clones 5, 7, and 8) were
incubated for 0, 4, 8, or 24 h in the presence of 2 nM BMP-2. After these
times cells were lysed, and myogenin, Id1, or ERK2 (as a loading
control) was immunodetected. B, C2C12 cells overexpressing myogenin
(Clones 5 and 8) or mock-transfected cells were incubated for 0, 4, 8, or
24 h in the presence of 2 nM BMP-2. Cells were lysed, and total RNA
was obtained as described. After blotting, myogenin or glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) (as a loading control) was de-
tected by hybridization using specific probes. C, cells of Clone 8 over-
expressing myogenin were incubated in the absence (0h BMP-2) or in
the presence for 4 h of 2 nM BMP-2 (4h BMP-2). After this time cells
were fixed, and myogenin was immunolocalized.
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myogenin was at levels comparable with those obtained in the
LLnL condition (Fig. 3B).
Id1 Is Sufficient to Mediate the BMP-2-induced Degradation
of Myogenin—One of the mediators of the antimyogenic re-
sponse of BMP-2 is the induction of the Id proteins that act as
dominant negative inhibitors of the tissue-specific helix-loop-
helix transcription factors (36, 37, 44). Given these effects, one
possibility was that the induction of Id by BMP-2, by seques-
tering E-factors, not only blocked the transcriptional activity of
myogenin but also served as an intermediate for the increase in
myogenin degradation. To test this, we transiently transfected
clones of C2C12 that expressed ectopic myogenin with Id1, and
we immunolocalized both proteins. Cells that did not express
Id1 clearly expressed myogenin in the nucleus (Fig. 4A). Id1
was localized in the nucleus and cytoplasm as described before
(45, 46). The overexpression of Id1 in the absence of BMP-2
always caused a decrease in the levels of myogenin.
To further confirm these effects in a more controlled system,
we used the Tet-Off system to generate an inducible Id1 ex-
pression system in C2C12 cells. Id1 expression in these cells
was an inverse function of the tetracycline in the medium.
Thus, in the presence of 100 ng/ml tetracycline in the medium
for 12 h Id1 expression was abolished (Fig. 4B). After removal
of tetracycline, expression levels increased with time but did
not exceed the physiological levels obtained after 4 h of stimu-
lation with BMP-2 (Fig. 4B). In these conditions of Id1 expres-
sion and in the absence of other effects caused by the presence
of BMP-2, the myogenin protein decreased in an inverse func-
tion of Id1. These results confirmed that Id1 was sufficient to
cause the drop in the levels of myogenin working as a mediator
for the effects of BMP-2.
E47 Protects Myogenin from Degradation Induced by BMP-
2—The E family of transcription factors is essential for the
transcriptional activity of the MRFs on the specific E-boxes of
the muscle-specific gene promoters (12, 13). If Id1 promotes
degradation of myogenin by releasing this factor from the het-
erodimer with the E-members, overexpression of an E-member
should prevent the effect of BMP-2. To evaluate this, we trans-
fected E47 expression constructs in C2C12 cells expressing
ectopic myogenin. Incubation for 8 h with BMP-2 caused a
large decrease in the myogenin expression in these cells (Fig.
5A). In contrast, most cells that overexpressed E47 (Fig. 5A,
green nuclei) maintained the expression of myogenin and were
refractory to the BMP-2 effect. 5% of the control cells that
FIG. 3. BMP-2 increases the degradation rate of myogenin. A,
C2C12 cells incubated for 48 h in differentiation medium were main-
tained for 1 h in the absence (BMP-2) or in the presence of 2 nM BMP-2
(BMP-2). After this time the protein synthesis inhibitor cycloheximide
(10 g/ml) was added. At the times indicated, cells were lysed, and
myogenin or Id1 was analyzed by Western blot. Values represent the
mean  S.E. of three independent experiments. B, C2C12 cells overex-
pressing myogenin (Clone 5) were preincubated for 15 min in the
presence of 50 M LLnL or vehicle. After this time cells were incubated
for 4 h in the presence of only LLnL, 2 nM BMP-2, or both as indicated.
Cells were lysed, and myogenin and Id1 were immunodetected by
Western blot as described.
FIG. 4. Id1 overexpression is sufficient to induce myogenin
degradation. A, C2C12 cells stably overexpressing myogenin (Clone 5)
were transiently transfected with a plasmid coding for Id1. After 48 h,
cells were fixed, and Id1 (green) and myogenin (red) were immuno-
stained using appropriate antibodies. Nuclei from cells were stained
using Hoechst 333258 (blue). Two images from two separate experi-
ments are shown. B, C2C12-pTISN-Id1 cells were incubated for 12 h in
the presence of 100 ng/ml tetracycline or its vehicle ethanol (0.1% final).
After this time 2 nM BMP-2 was added (BMP) for 4 h or not (), or the
cells were rinsed five times with PBS and incubated in the absence of
tetracycline for 4 h (T 4h) or 8 h (T 8h). Cells were lysed, and
myogenin, Id1, and -actin were immunodetected by Western blot as
described. A representative experiment is shown.
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expressed green fluorescent protein still maintained the myo-
genin expression after 8 h of incubation in the presence of
BMP-2. In contrast, 90  4% of cells that overexpressed E47
maintained the myogenin expression. To biochemically confirm
these data, mock or E47 expression plasmids were cotrans-
fected with a plasmid that encoded puromycin resistance. After
24 h of transfection, puromycin was added to the culture me-
dium to select cells that had incorporated the expression plas-
mids. The resistant cells were incubated for 0, 4, or 8 h in the
presence of 2 nM BMP-2. Overexpression of E47 blocked myo-
genin degradation even 8 h after the addition of BMP-2 (Fig.
5B). In contrast, myogenin was degraded by BMP-2 in the
control cells that expressed pcDNA3. These results confirmed
the hypothesis that Id was a mediator for the effects of BMP-2
observed through a mechanism that involved the sequestering
of endogenous E-proteins.
To confirm these data obtained analyzing the endogenous
myogenin protein in C2C12 cells, we expressed myogenin in
HEK-293 cells. Basal levels of myogenin expression in these
cells were low (Fig. 6A). As it was observed in C2C12 cells,
incubation with LLnL caused a strong increase in the levels of
myogenin. Co-expression of E47 with myogenin caused the
stabilization of the protein in the absence of LLnL, confirming
the stabilizing role of heterodimerization with E-proteins. In
contrast, addition of a Myc6 tag to the N terminus of myogenin
blocked its high degradation rate as it was highly expressed in
the absence of LLnL (Fig. 6A). Finally, to analyze the impor-
tance of myogenin-E47 heterodimer formation in myogenin
stability, we made similar assays using two E47 deletion mu-
tants (E47HLH, defective in heterodimer formation (47), and
E47HLH, which contains the bHLH). The E47 mutant unable
to heterodimerize with myogenin was also defective in myoge-
nin stabilization (Fig. 6B). In contrast, the mutant containing
the bHLH stabilized myogenin even more that the wild type
form of E47. All of these data indicated that myogenin protein
stability was strongly enhanced in the heterodimer state with
E-proteins, which would be competed by the presence of Id1.
DISCUSSION
BMP-2 induces the osteoblastic phenotype of mesenchymal
cells and causes a concomitant blockade of the myogenic pro-
FIG. 5. E47 overexpression is sufficient to protect myogenin
from degradation induced by BMP-2 in C2C12 cells. A, C2C12
cells stably overexpressing myogenin (Clone 5) were transiently trans-
fected with a plasmid coding for E47. 48 h after the transfection cells
were incubated for 8 h in the presence (8h BMP-2) or in absence (0h
BMP-2) of 2 nM BMP-2. Cells were fixed, and E47 (green) and myogenin
(red) were immunostained with appropriate antibodies. As a control
nuclei from cells were stained with Hoechst 333258. We present here
two representative images from three independent experiments. B,
C2C12-myogenin Clone 5 cells were transiently transfected with a
plasmid coding for E47 or pcDNA3 (control cells) together with a plas-
mid coding for resistance for puromycin. 24 h after transfection cells
were treated with puromycin for 12 h. Selected cells were treated with
2 nM BMP-2 for 0, 4, or 8 h. Cells were lysed, and E47, myogenin, and
Id1 were analyzed by Western blot.
FIG. 6. The helix-loop-helix of E47 protects myogenin from
degradation in HEK-293 cells. A, HEK-293 cells were transiently
transfected with a plasmid coding for myogenin or a Myc6 N-terminally
tagged myogenin together or not with a plasmid coding for E47. 24 h
after transfection cells were treated or not with LLnL for 12 h. Cells
transfected with E47 were not treated with LLnL. Cells were lysed, and
myogenin, Id1, and actin were analyzed by Western blot. B, HEK-293
cells were transiently transfected with pcDNA3, a plasmid coding for
myogenin together or not with a plasmid coding for wild type E47, E47
lacking the helix-loop-helix (E47HLH, which codes for amino acids
1–386), or E47 containing the helix-loop-helix (E47HLH, which codes
for amino acids 387–649) all tagged with Myc. 24 h after transfection
cells were treated or not with LLnL for 12 h. Cells were lysed, and
myogenin, E47 (Myc), and actin were analyzed by Western blot.
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gram both in vivo and in vitro (1, 16, 36). Moreover, even in
cells that ectopically overexpress myogenic factors, such as
MyoD or myogenin, BMP-2 inhibits the myogenic activity of
these factors (16). The induction of the osteoblastic program
by BMP-2 is a result, at least in part, of the induction of the
transcription factors Cbfa-1 and Osterix (48, 49), whereas
the inhibition of the myogenic program is mainly caused by the
induction of inhibitors of the myogenic bHLH, such as Ids (36,
37), through the direct stimulation of their promoter by Smads
(44). The inhibitory function of Id proteins has been attributed
to their ability to inhibit the formation of transcriptionally
active heterodimer complexes between myogenic bHLH and
E-proteins (28, 29). Our results provide direct biochemical ev-
idence for an additional regulatory mechanism of repression of
myogenic bHLH by Id proteins. Induction of Id1 not only se-
questers E-proteins but also promotes enhanced degradation of
myogenin. This dual and redundant regulation by Id1 would
ensure a stronger and more abrupt short term control of myo-
genin function. The decrease in the levels of myogenin causes
the blockade of the autostimulatory loop promoted by these
myogenic bHLH factors (39, 50) and elicits the decrease in
myoblast-specific markers. Moreover, these effects could pro-
mote cells already expressing myogenin to change their com-
mitment and lose the myoblastic phenotype. Such effects con-
stitute an essential feature in multipotent cells that express
distinct sets of master genes and could trigger distinct differ-
entiation pathways, such as muscle satellite cells (51).
Myogenin (Ref. 39 and this work) and other helix-loop-helix
factors such as MyoD (50, 52, 53) and Id proteins (54, 55)
have a short half-life of between 30 and 60 min. All of these
proteins are degraded by mechanisms that involve ubiquiti-
nation and translocation to the proteasome. For instance,
MyoD, Id1, and Id2 are degraded by the proteasome after its
ubiquitination in the N-terminal residue without the partic-
ipation of internal lysines (56–58). Recent results obtained
with MyoD and Id1 indicate that the internal lysine-depend-
ent pathway for protein ubiquitination and degradation
seems to be more active in the cytoplasm, whereas the N
terminus-dependent pathway would be the most important in
the nucleus (58, 59). Degradation of myogenin occurs mainly
in the nucleus (59, 60) in contrast with other nuclear proteins
that are degraded in the cytoplasm (61, 62). Furthermore, our
results show a protection of myogenin degradation by the
addition of a Myc6 tag to the N-terminal residue (Fig. 6A).
Thus, it seems likely that myogenin would be degraded using
the N-terminal pathway as is MyoD in the nucleus. Further
studies would be required to confirm this hypothesis.
We have shown that overexpression of E47 is sufficient to
overcome the degradation induced by BMP-2. Thus, this pro-
tein may be the limiting factor that accelerates a faster degra-
dation of myogenin in clones that express lower amounts of
myogenin (Fig. 2). The same effect was observed for Id proteins;
overexpression of E47 attenuates the rapid elimination of Id
proteins (55, 63). Moreover, Mash1, a neurogenic bHLH mem-
ber, is degraded by the proteasome in the absence of its E-part-
ner.2 Similarly, Id1 accelerates the degradation of MyoD in
assays in vitro through direct interaction between them (53).
However, myogenin does not interact directly with Id proteins
(64), which discards the possibility of myogenin having a mech-
anism similar to that of MyoD. In the case of MyoD, its phos-
phorylation by the complex cdk2-cyclin E in Ser200 promotes
the degradation of the transcription factor (52, 65), a mecha-
nism implicated in the blockade of MyoD activity in proliferat-
ing myoblasts. A similar mechanism is not likely to be involved
in the case of myogenin, which is absent in proliferating myo-
blasts (9, 14, 66) and lacks a residue equivalent to the Ser200 of
MyoD. In fact, the hyperphosphorylated form of myogenin is
more stable than the hypophosphorylated form (39), indicating
that phosphorylation of myogenin by an unknown kinase would
have protective effects rather that stimulate degradation.
A possible mechanism involved in the protection of myogenin
from degradation would implicate the formation of a stable
heterodimer with E-protein, whereas free myogenin, not bound
to the E-protein, would be targeted to the proteasome. One
possible explanation is that monomeric myogenin serves as a
substrate for an E3-ubiquitin ligase. Formation of myogenin-
E-protein heterodimers either could hinder the recognition
sites for the E3-ligase directly or could promote posttransla-
tional modifications that prevent this recognition. On the basis
of our results, we propose a new posttranscriptional mecha-
nism for the negative control of the myogenic program by
BMP-2. This mechanism involves induction of Id1 by BMP-2,
which, through its ability to block formation of protective com-
plexes with E-proteins, not only blocks myogenin transcrip-
tional activity but also is sufficient to increase monomeric
myogenin, which is then rapidly degraded.
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